Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CECYDE: Cemiplimab plus chemotherapy by baseline cytidine deaminase activity in advanced squamous NSCLC
2024-517799-40-00Phase 2Authorised
- Sponsor
- GOIRC
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab in Pulmonary squamous cell carcinoma (2 cohorts), sponsored by GOIRC. Primary endpoint: Overall Survival (1-year survival rate in low CDA cohort). Planned start Jul 2026; status: authorised.
02
Drugs
cemiplimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2024-517799-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517799-40-00.